Hospital Samaritano - Botafogo (RJ), Brazil.
Universidade Federal do Rio de Janeiro, Instituto do Coração Edson Saad - Rio de Janeiro (RJ), Brazil.
Rev Assoc Med Bras (1992). 2021 Oct;67(10):1466-1471. doi: 10.1590/1806-9282.20210661.
Hydroxychloroquine and Ivermectin are advocated as potential treatments for coronavirus disease 2019 (COVID-19) despite the lack of supportive clinical evidence. In this study, outcomes associated with Hydroxychloroquine and/or Ivermectin were determined in a series of patients with confirmed COVID-19 from a single institution in Brazil.
Consecutive patients admitted between March and July 2020 were retrospectively analyzed and divided into four treatment categories: no treatment (Group 0), Ivermectin only (Group I), Hydroxychloroquine only (Group II), and Hydroxychloroquine and Ivermectin (Group III). Intensive care unit admission, mechanical ventilation, and death were compared between the Groups.
A total of 230 patients were included, with the following treatment distribution: 35.2% (0), 9.1% (I), 48.3% (II), and 7.4% (III). Groups I, II, and III had the higher rates of Intensive care unit admission, mechanical ventilation, or death (0: 23.5% versus I: 38.1% versus II: 37.8% versus III: 70.6%, p=0.002), and the greatest mortality was found in Group III (0 versus III: 13.6% versus 35.3%, p=0.03). In the multivariate analysis, Hydroxychloroquine remained significantly associated with death (OR 3.3, 95%CI 1.1-9.6, p=0.03).
In a series of consecutive hospitalized patients with COVID-19, Ivermectin was not associated with improved outcomes and Hydroxychloroquine may have resulted in a harmful effect.
羟氯喹和伊维菌素被提倡作为治疗 2019 年冠状病毒病（COVID-19）的潜在药物，尽管缺乏支持的临床证据。在这项研究中，对来自巴西一家机构的一系列确诊 COVID-19 患者中使用羟氯喹和/或伊维菌素的结果进行了确定。
回顾性分析了 2020 年 3 月至 7 月间连续入院的患者，并将其分为四组治疗类别：未治疗（第 0 组）、仅用伊维菌素（第 I 组）、仅用羟氯喹（第 II 组）和羟氯喹和伊维菌素（第 III 组）。比较各组之间的重症监护病房（ICU）入院、机械通气和死亡情况。
共纳入 230 例患者，其治疗分布如下：35.2%（第 0 组）、9.1%（第 I 组）、48.3%（第 II 组）和 7.4%（第 III 组）。第 I、II 和 III 组 ICU 入院、机械通气或死亡的发生率更高（第 0 组：23.5%，第 I 组：38.1%，第 II 组：37.8%，第 III 组：70.6%，p=0.002），第 III 组死亡率最高（第 0 组：13.6%，第 III 组：35.3%，p=0.03）。多变量分析显示，羟氯喹与死亡显著相关（OR 3.3，95%CI 1.1-9.6，p=0.03）。
在一系列连续住院的 COVID-19 患者中，伊维菌素并未改善结局，而羟氯喹可能产生了有害影响。
